HK1032752A1 - Compositions and methods for extending the action of clostridial neurotoxin - Google Patents

Compositions and methods for extending the action of clostridial neurotoxin

Info

Publication number
HK1032752A1
HK1032752A1 HK01103477A HK01103477A HK1032752A1 HK 1032752 A1 HK1032752 A1 HK 1032752A1 HK 01103477 A HK01103477 A HK 01103477A HK 01103477 A HK01103477 A HK 01103477A HK 1032752 A1 HK1032752 A1 HK 1032752A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
action
extending
clostridial neurotoxin
Prior art date
Application number
HK01103477A
Other languages
English (en)
Inventor
J Oliver Dolly
Kei Roger Aoki
Paiva Anton De
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1032752A1 publication Critical patent/HK1032752A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK01103477A 1998-04-29 2001-05-21 Compositions and methods for extending the action of clostridial neurotoxin HK1032752A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8347298P 1998-04-29 1998-04-29
PCT/US1999/008303 WO1999055359A1 (en) 1998-04-29 1999-04-15 Compositions and methods for extending the action of clostridial neurotoxin

Publications (1)

Publication Number Publication Date
HK1032752A1 true HK1032752A1 (en) 2001-08-03

Family

ID=22178574

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01103477A HK1032752A1 (en) 1998-04-29 2001-05-21 Compositions and methods for extending the action of clostridial neurotoxin

Country Status (10)

Country Link
US (1) US20040228881A1 (de)
EP (1) EP1073455B1 (de)
JP (2) JP2002512977A (de)
AT (1) ATE251463T1 (de)
AU (1) AU3748499A (de)
CA (1) CA2328111A1 (de)
DE (1) DE69911944T2 (de)
ES (1) ES2207208T3 (de)
HK (1) HK1032752A1 (de)
WO (1) WO1999055359A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873244A3 (de) * 1999-06-02 2008-04-02 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2009131166A1 (ja) 2008-04-25 2009-10-29 国立大学法人 千葉大学 インスリン様増殖因子結合タンパク質を含有するWntシグナル伝達阻害剤
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
AU2001268080B2 (en) * 2000-05-23 2004-09-23 Neurologix, Inc. Glutamic acid decarboxylase (gad) based delivery systems

Also Published As

Publication number Publication date
ATE251463T1 (de) 2003-10-15
JP2006063085A (ja) 2006-03-09
DE69911944D1 (de) 2003-11-13
DE69911944T2 (de) 2004-07-22
EP1073455B1 (de) 2003-10-08
WO1999055359A1 (en) 1999-11-04
CA2328111A1 (en) 1999-11-04
AU3748499A (en) 1999-11-16
US20040228881A1 (en) 2004-11-18
ES2207208T3 (es) 2004-05-16
EP1073455A1 (de) 2001-02-07
JP2002512977A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
HK1032752A1 (en) Compositions and methods for extending the action of clostridial neurotoxin
BR9608402A (pt) Oligonucleotìdeo anti-sentido, e, processos para inibição da expressão do raf humano, da hiperproliferação de células e para tratamento da condição proliferativa anormal.
DE69102106D1 (de) Elektrochemische Zellen enthaltender Apparat, bei dem der Reformer, die Mischdüse und der Mischverteiler integriert sind.
WO1996006108A3 (en) Cyclic cs-1 peptidomimetics, compositions and methods of using the same
EP0685233A3 (de) Thieno 1,5 benzodiazepin zur Behandlung gastrointestinales Beschwerden.
WO1999066959A3 (en) Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival
HUP9801767A3 (en) Viral vectors their use for treating hyperproliferative disorders, in particular restenosis
MX210213B (es) Procedimiento de obtencion de polimeros hidrosolubles, polimeros obtenidos y sus usos.
HK1030338A1 (en) Treatment of schizophrenia with ampakines and neuroleptics
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
EP0871496A4 (de)
DE69709315D1 (de) Weichmacherlotionzusammensetzung, ihre verwendung in der papierherstellung und papierprodukt
ATE261972T1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
WO2000066730A3 (en) Laminin 2 and methods for its use
HUP0002101A3 (en) Fluoroether compositions, process for producing them and methods for inhibiting their degradation
AU6714396A (en) Methods and compositions for treating cell proliferative disorders
ATE238918T1 (de) Reifen der einen elektrischen generator zur speisung von in dem reifen eingebauten vorrichtungen enthält, und verfahren zur dessen herstellung.
IL131014A0 (en) Methods for cultivating cells and propagating viruses
ZA962755B (en) 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives.
EP0845495A3 (de) Zellulosepartikeln, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1002793A4 (de) Physiologisch aktive substanzen tkr2449, verfahren zu ihrer herstellung und mikroorganismen
AU1099699A (en) Cell regulatory genes, encoded products, and uses related thereto
EP0820278A4 (de) Nicht-immunogene biokompatible makromolekulare menbranzusammensetzungen und verfahren zu deren herstellung und verwendung
PT1143917E (pt) Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico
ZA9810759B (en) Proliferatively active product for treating proliferating cells.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080415